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Evidence for a Novel Mechanism of the PAK1 Interaction
with the Rho-GTPases Cdc42 and Rac
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Department of Biochemistry and Molecular Medicine, The George Washington University Medical Center, Washington, D.C., United of States of America

Abstract
P21-activated kinase 1 (PAK1) is activated by binding to GTP-bound Rho GTPases Cdc42 and Rac via its CRIB domain. Here,
we provide evidence that S79 in the CRIB domain of PAK1 is not directly involved in this binding but is crucial for PAK1
activation. S79A mutation reduces the binding affinity of PAK1 for the GTPases and inhibits autophosphorylation and kinase
activity of PAK1. Thus, this mutation abrogates the ability of PAK1 to induce changes in cell morphology and motility and to
promote malignant transformation of prostate epithelial cells. We also show that growth of the prostate cancer cell line PC3
is inhibited by the treatment of a PAK1-inhibiting peptide comprising 19 amino acids centered on S79, but not by the PAK1
peptide containing the S79A mutation, and that this growth inhibition is correlated with reduced autophosphorylation
activity of PAK1. Together, these findings demonstrate a significant role of S79 in PAK1 activation and provide evidence for a
novel mechanism of the CRIB-mediated interaction of PAK1 with Cdc42 and Rac.
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HIV-1 TAT protein transduction domain-mediated delivery of
macromolecules has emerged as an alternative approach for the
internalization of proteins into the cell from the external
environment [24]. PAK peptides have been also examined by
two groups in different methods; 1) treatment of the PAK peptide
(aa 11–23) that interacts with NCK [25]; 2) expression of PAK1
inhibitory domain (aa 83–149) [26].
The crystal structure of the Cdc42-PAK1 complex revealed that
the CRIB domain of PAK interacts with Cdc42 by forming an
intermolecular b-sheet between residues Y40-I46 of Cdc42 and
I76-H83 of PAK but that this interaction seems to be disrupted by
the presence of a b-bulge in PAK formed by the sequence 79SDF81
[4]. To get insights into the role of this sequence, here we
investigated the effect of the mutation at S79, one of the three
residues of the 79SDF81 sequence on the regulation of PAK1
activity. Our biochemical and cell biological studies have
demonstrated that S79 plays a crucial role in the PAK1 interaction
with Cdc42 and Rac1 and is required for PAK1-mediated
malignant transformation of prostate epithelial cells. Thus, this
study uncovers a previously unappreciated role of S79 in the
regulation of PAK1 activity and demonstrates a novel concept for
the activation of PAK1 by the GTPases.

Introduction
PAK1 is a major downstream effector of the Rho-GTPases
Cdc42 and Rac, which act as molecular switches that transduce
various extracellular signals into intracellular responses [1]. PAK1,
the best-characterized member of the PAK family, forms a transinhibited dimer in its inactive state, in which the catalytic domain
of one PAK1 monomer is blocked by the autoinhibitory domain
(AID) of the other [2,3]. This autoinhibitory conformation is
disrupted by binding of the GTP-bound Cdc42 and Rac to the
CRIB (Cdc42/Rac-interactive binding region) domain [4,5,6],
leading to autophosphorylation at specific sites including T423
within the activation loop and consequent activation of PAK1
[7,8]. Efficient activation of PAK1 requires its membrane
targeting. PAK1 is recruited to the plasma membrane via the
SH3-containing proteins Nck and Grb2 [9,10,11], where it may be
activated by signaling molecules such as PDK1 kinase [12],
sphingosine [13,14] and PIP2 [15] in a manner independent of the
GTPases.
PAK1 is frequently overexpressed and hyperactivated by
dysregulation of a number of signaling pathways in human cancer
cells that are stimulated by growth factor receptors such as EGFR,
PDGFR, and VEGFR [16]. The activated PAK1 in turn promotes
cancer cell invasion and metastasis by phosphorylating key
regulators involved in cytoskeleton reorganization, such as Lim
kinase (LIMK) [17,18] and the P41-ARC subunit of the ARP2/3
[19]. PAK1 activation also stimulates anti-apoptotic pathways,
such as the Pak-Raf1-Bad [20,21] and NFkB [20] pathways,
rendering PAK1 attractive as a cancer therapeutic target [22].
There has been a rapid expansion in the development of peptides
as potential drugs for cancer therapy over the last decade [23].
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Results and Discussion
PAK1S79 Plays an Important Role in Autophosphorylation
and Kinase Activities of PAK1
PAK1 interacts with Cdc42 and Rac via the CRIB domain
(amino acid residues 74-88) [1]. A study indicated that 79SDF81
motif is positioned near the center of the CRIB domain and
appears to disrupt the intermolecular b-sheet interaction between
1
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Figure 1. S79 within the CRIB domain is crucial for autophosphorylation and kinase activity of PAK1. Overall Structures of CRIP domain
of PAK1 and Sequence Comparisons. (A) Ribbon diagram showing a structural overview of CRIP domain of PAK1 (red) with bound Cdc42 (blue). Data
Bank ID number 1E0A and visualized using Molsoft ICM Browser (Molsoft, L.L.C., San Diego, CA, USA). (B) Multiple sequence alignment of the amino
acid sequence of PAK1 from 17 species. (C) Western blot analysis of phosphorylation of T423, S199, and S144 and of GFP-PAK1WT or GFP-PAK1S79A.
(D) The kinase activity of PAK1 (GFP-PAK1WT or GFP-PAK1S79A) was assessed by in vitro phosphorylation assay using MBP (upper) or DLC1 peptide
(lower) as substrate. (E) Western blot analysis of the effect of S79A mutation on the PAK1 autophosphorylation using anti-T423 and anti-S144
phospho-specific PAK1 antibodies. Cells were unstimulated (2) or stimulated (+) by EGF (100 ng/ml).
doi:10.1371/journal.pone.0071495.g001

PAK1S79 is Required for the Interaction of PAK1 with Rac1

residues Y40-I46 of Cdc42 (blue) of Cdc42 and I76-H83 of PAK
(red) [4] (Fig. 1A). Our sequence alignment showed that this motif
is conserved only in higher eukaryotic organisms, suggesting
diverse mechanisms for the regulation of PAK1 activity (Fig. 1B).
Increased PAK1 activity is associated with autophosphorylation at
specific sites, including S144, S199 and T423 [14]. To address
whether S79 of PAK1 (PAK1S79) is required for autophosphorylation and kinase activity of PAK1, we assessed phosphorylation
states of these residues in PAK1 (WT) and PAK1S79A by IP/
Western blot analysis and PAK1 kinase activity by in vitro kinase
assay, respectively. Our results show that S79A mutation
significantly decreases the phosphorylation of the three residues
(Fig. 1C) and kinase activity of PAK1 toward the PAK1 substrates
MBP (myelin basic protein) and DLC1 (dynein light chain 1)
peptide (Fig. 1D). PAK1 activation is stimulated by a variety of
factors including epidermal growth factor (EGF) [16]. We found
that S79A mutation markedly decreases EGF-induced PAK1
autophosphorylation at both S144 and T423 (Fig. 1E).
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Given that PAK1 activation is induced by the binding of the
activated GTPase to the CRIB domain [4,5,6], we next examined
S79A mutation effect on the PAK1 interaction with the Cdc42
and Rac1 GTPases. To this end, GFP-PAK1 and GFP-PAK1S79A
were coexpressed with Cdc42 or Rac1 in 293T cells, and their
interaction was assessed by Co-IP/Western blot analysis. Wild
type PAK1 was shown to interact with Cdc42 (Fig. 2A) and Rac1
(Fig. 2B). However, the ability of PAK1S79A to interact with the
GTPases was markedly decreased; the binding affinity of
PAK1S79A for Cdc42 was reduced by ,3-fold (Fig. 2A), whereas
the Pak1 interaction with Rac1 was barely detectable (Fig. 2B).
GST pull-down analysis also revealed a direct interaction between
GFP-PAK1 (WT) and GST-Cdc42 (C) or GST-Rac1 (D) bound to
GST-beads, whereas PAK1S79A mutant has reduced affinity for
both GTPases, for Rac1 in particular. However, we also found
that S79D mutation does not affect in PAK1 activity towards MBP
(Fig. 2E) and in the PAK1 interaction with Rac1 (Fig. 2F).

2
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Figure 2. S79A mutation impairs the interaction of PAK1 with Cdc42 and Rac1. (A) Interaction between Myc-Cdc42 and GFP-PAK1. GFPPAK1WT or GFP-PAK1S79A was coexpressed with Myc-Cdc42 in 293T cells. Cell extracts were immunoprecipitated with anti-GFP antibody (IP) and then
immunoblotted with anti-GFP or anti-Myc antibody (left). (B) Interaction between GFP-Rac1 and Myc-PAK1. Cell extracts were immunoprecipitated
with anti-Myc antibody (IP) and then immunoblotted with anti-Myc or anti-GFP antibody. (C and D) Cell lysates prepared from 293T cells expressing
GFP- PAK1WT or GFP- PAK1S79A were incubated with GST-Cdc42 (C) or GST-Rac1 (D) bound to GST-beads. Upper panels, Western blot analysis of the
eluates from the beads using anti-GFP antibody; Lower panels, the blots were stained with Ponceau S Stain. MW markers; molecular weight markers.
doi:10.1371/journal.pone.0071495.g002
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Figure 3. The S79A mutation impairs the ability of PAK1 to regulate cell morphology and motility. (A) Wild type (a–c) and PAK12/2 (d–f)
MEF cells were stained with the high affinity F-actin probe Phalloidin (red) and DAPI (blue). PAK12/2 MEF cells expressing GFP-PAK1WT (WT, g–i) and
GFP-PAK1S79A (S79A, j–l) were stained with Phalloidin (red) and DAPI (blue) and visualized by GFP fluorescence (green). (B) Quantification of the
length and width (L/W) ratio of MEF cells was obtained as described previously [44]. (C) Wound healing migration assays of PAK12/2 MEF cells
infected with lentivirus expressing the vector control, GFP- PAK1WT, or GFP-PAK1S79A. Results were expressed as the percentage of the remaining area
determined by normalizing the area of wound after 24 h to the initial wound area at 0 h (set to 100%). Each bar represents the mean 6 S.D of five
fields measured.
doi:10.1371/journal.pone.0071495.g003
2

MEF cells displayed a more rounded morphology (Fig. 3A, d–f).
Expression of GFP-PAK1 in PAK12/2 MEF cells restored the
wild type cell shape (Fig. 3A, g–i), whereas GFP-PAK1S79A
expression did not rescue this defect (Fig. 3A, j–l). F-actin was
colocalized with PAK1, as observed previously in Swiss 3T3 cells
[28]; however, this colocalization was significantly reduced in
MEF cells expressing PAK1S79A (Fig. 3A and Fig. S1). MEF cells
expressing GFP-PAK1S79A exhibited 1.5,2 fold decrease in the
ratio of length to width (L/W), compared with MEF cells
expressing GFP-PAK1, whereas those cells expressing GFP-

The S79A Mutation Impairs the Ability of PAK1 to Induce
Changes in Cell Morphology and Motility
PAK1 is translocated to the focal adhesions and membrane
ruffles [27,28] and the sites of cortical actin remodeling [29] in
stimulated cells. We examined the functional importance of
PAK1S79 by comparing the morphology and motility of PAK12/2
MEF (mouse embryonic fibroblast) cells expressing GFP-PAK1
and GFP-PAK1S79A (Fig. 3A). Wild type MEF cells (PAK1+/+)
exhibited a bipolar fusiform shape (Fig. 3A, a–c), whereas PAK12/
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Figure 4. S79A mutation abolishes the migration activity of PAK1. The benign prostate RWPE-1 cells infected with lentivirus expressing the
vector plasmid, GFP- PAK1WT (WT), or GFP-PAK1S79A (S79A) were used for experiments (A) to (E). (A) The invasion rate was determined by counting
the cells that migrated through BME-coated inserts in the Transwell Boyden chamber and expressed as the percentage relative to control (vector).
Each bar represents the mean 6 S.D of five fields counted. a) Western blot analysis of PAK1 expression using anti-GFP antibody. Actin was used as an
internal control. (B) The S79A mutation impairs the ability of PAK1 to regulate formation of membrane ruffles of cells. RWPE-1 cells infected with
lentivirus expressing the vector plasmid (a–c), GFP-PAK1WT (WT, d–f) or GFP-PAK1S79A (S79A, g–i) were stained with Phalloidin (red) and DAPI (blue)
and visualized by GFP fluorescence (green). (C) Quantification of the cells with membrane ruffles (B). (D) Wound healing migration assays of RWPE-1
cells expressing GFP-PAK1 or GFP-PAK1S79A. (E) Each bar represents the mean 6 S.D of five fields measured in (D).
doi:10.1371/journal.pone.0071495.g004

PAK1S79D displayed ,1.5 fold decrease in the ratio of L to W
(Fig. 3B). Wound healing migration assays showed that impaired
ability of PAK12/2 MEF cells to migrate into, and close to, the
wound was restored by expression of GFP-PAK1 but not of GFPPAK1S79A (Fig. 3C).
Next, we compared the ability of wild type and mutant (S79A)
PAK1 proteins to confer a migration phenotype on the benign
prostate RWPE-1 cells. To this end, RWPE-1 cells were infected
with lentivirus expressing the vector plasmid, GFP-PAK1, or GFPPAK1S79A (S79A). Western blot analysis indicated no significant
difference in the expression of GFP-PAK1 and GFP-PAK1S79A in
RWPE-1 cells (Fig. 4Aa)). Cell invasion assay showed that
expression of GFP-PAK1, but not of GFP-PAK1S79A, confers an
invasive phenotype to RWPE-1 cells (Fig. 4A). We also examined
cell morphology of RWPE-1 cells expressing PAK1 or PAK1S79A.
The formation of membrane ruffles was increased by ,2.5-fold
(Fig. 4C) in RWPE-1 cells expressing GFP-PAK1 (Fig. 4B, d–f),
compared with cells expressing GFP-PAK1S79A (Fig. 4B, g–i) or
control cells (Fig. 4B, a–c). These results are consistent with
previous observations that PAK1 regulates the formation of
membrane ruffles of Swiss 3T3 cells [28] and breast cancer cells
[30]. We also found that RWPE-1 cells fill ,30% and ,60% of
the wounded areas by expression of PAK1 and PAK1S79A,
respectively, at 24 h after scratching (Fig. 4D and Fig. 4E). These
observations demonstrate that S79 is crucial for PAK1-mediated
cell migration.

containing the CRIB (PAK167–84) was chemically synthesized
(Fig. 5A) and fused to the C-terminus of the TAT protein
polybasic sequence to facilitate entry into cells as a protein
transduction domain [31,32]. PC3 cells were treated with the
peptide at low (2 mg/ml) and high (20 mg/ml) concentrations and
were examined for cell growth by MTT assay. We found that
treatment of the PAK1 peptide has ,2-fold inhibitory effect at
high dose used (Fig. 5B). To confirm the significance of S79 in the
activation process of PAK1 as described above, we also generated
a TAT-PAK167–84 peptide with S79A mutation and tested its
ability to inhibit PAK1 activation. Western blot analysis indicated
that S144 phosphorylation is reduced by ,40% by the treatment
of the PAK1 peptide but is not affected by the treatment of the
PAK1 (S79A) peptide (Fig. 5C). We also examined the inhibitory
effect of the PAK1-inhibiting peptide on the morphology PAK1+/+
MEF cells (Fig. 5D). The bipolar fusiform shape of MEF cells
(PAK1+/+) was changed to a more rounded morphology by
treatment of the PAK1-inhibiting peptide, whereas the treatment
of the PAK1 (S79A) peptide has little effect on the morphology of
MEF cells (Fig. S2).

Conclusion
The CRIB proteins such as PAK1-3 kinases [28], ACK tyrosine
kinases [33,34] and the Wiscott-Aldrich-syndrom proteins
(WASPs) [35,36] are activated by direct binding to Cdc42 [37].
While PAK binds to both Cdc42 and Rac, ACK and WASP do
not bind to Rac [4]. Structural analyses indicate that the CRIB
motif of all the three proteins make an intermolecularb-sheet
interaction with the b2 strand of Cdc42 [4,38,39]. Thus,
mutations of the amino acid residues that are evolutionarily
conserved from human to Drosophila such as I75, S76 and P78
(for sequence alignment, see Fig. 1B) dramatically reduces the

A PAK1-inhibiting Peptide (TAT-PAK167–84) Blocks the
Growth of the Prostate Cancer Cell Line PC3
Given that PAK1 activation is triggered by interaction with
Cdc42 and Rac1, we examined whether PAK1 activity is reduced
by a PAK1-inhibiting peptide. Towards this aim, a peptide
PLOS ONE | www.plosone.org
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Figure 5. A PAK1-inhibiting peptide blocks the growth of the prostate cancer cell PC3. (A) Schematic design of a PAK1-inhibiting peptide
(TAT-PAK1 peptide; PAK peptide, aa 67–84). The CRIB domain is underlined. (B) PC3 cells were treated with 2 mg/ml or 20 mg/ml of each peptide and
examined by MTT assay for 4 days. Cell viability over time was expressed as fold increase, compared with the initial absorbance at day 0. Error bars
represent mean 6 S.D (n = 5). (C) Western blot analysis of S144 phosphorylation of PAK1 in PC3 cells treated with TAT peptide, TAT-PAK1 peptide
(WT) or TAT-PAK1 (S79A). (D) MEF cells were stained with the high affinity F-actin probe Phalloidin (red) and DAPI (blue) after treatment with with TAT
peptide, TAT-PAK1 peptide (WT) or TAT-PAK1 (S79A) (left). Quantification of the length and width (L/W) ratio of MEF cells was obtained as described
previously (right). (E) A structural overview of CRIP domain of PAK1 (red, 75–83 a.a) with bound Cdc42 (blue, 40–46 a.a). Data Bank ID number 1E0A
and visualized using Molsoft ICM Browser (Molsoft, L.L.C., San Diego, CA, USA).
doi:10.1371/journal.pone.0071495.g005

PAK1 may bind to Cdc42 and Rac1 by different mechanisms and
that S79 may play a key role in enabling PAK1 to distinguish
Cdc42 and Rac1. This view is reinforced by the previous work that
PAKs bind Rac1 with higher affinity than Cdc42. [41]. The
crystal structure of the PAK1-Rac1 complex will help to elucidate
the role of S79 in the interaction with and activation by Rac1.

binding affinity of PAK for Cdc42 [40]. S79 is conserved only in
higher eukaryotes and one of three residues (79SDF81) forming a bbulge that disrupts this interaction [4]. The structure of the Cdc42PAK complex infers that S79 might interact with the V42 of
Cdc42 [4] (Fig. 5E), whose mutation does not significantly affect
the interaction of Cdc42 with PAK [39]. Hence, S79 is not
essential for the PAK interaction with Cdc42. This may be in line
with our finding that S79A mutation has little effect on the PAK1Cdc42 interaction (Fig. 2A–Fig. 2D). However, this mutation is
shown to abolish the binding of PAK1 to Rac1, suggesting that
PLOS ONE | www.plosone.org
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boiling the beads in sodium dodecyl sulfate (SDS) sample buffer for
5 min and were resolved in SDS-polyacrylamide gels. Western
blot analysis was performed, as described previously [42].

Materials and Methods
Reagents and Antibodies
Anti-Pak1, Pak1-pT423, Pak1-pS119 and Pak1-pS144 antibodies were from Cell Signaling. Normal mouse Protein A/G PLUSAgarose beads, IgG, anti-actin, anti-c-Myc, and anti-GFP antibodies
were from Santa Cruz Biotechnology. Recombinant EGF was
from Millipore. Alexa Fluor 568 conjugated-phalloidin was from
Invitrogen.

Cell Invasion and Migration Assays
Cell invasion assay was performed using the cell invasion kit
(Transwell Boyden’s chamber with TranswellH Permeable Support
Inserts Coated with CultrexH BME (basement membrane extract)
Corning Costar) according to the manufacture’s instruction. For
the cell migration assay, confluent RWPE-1 or MEF cells were
scratched with a P-200 pipette tip to cause wounding and
subjected to the wound healing assay as described previously [42].

Cell Culture
The RWPE-1 cells were grown in keratinocyte serum-free
medium (K-SFM) containing bovine pituitary extract and
epidermal growth factor, as described previously [42]. MEF,
PC3, and 293T cells were cultured in RPMI 1640 or DMEM
containing 10% FBS and penicillin/streptomycin at 37uC in a
humidified atmosphere of 5% CO2. PAK1 wild type and PAK12/
2
murine embryonic fibroblasts (MEFs) were kindly provided by
Dr. Rakesh Kumar [43]. MEFs were isolated from day 13.5 wildtype or Pak12/2 embryos. Wild-type and Pak12/2 MEFs were
immortalized with SV40 T antigen and were maintained in DME
supplemented with 12% FBS. RWPE-1, PC3, and 293T cells cell
lines used in this study were obtained from the American Type
Culture Collection (ATCC; Rockville, MD).

MTT Cell Proliferation Assays
For MTT cell proliferation assay, PC3 cells were cultured in 96well microplate. Cell growth was evaluated by replacing the
culture media with 200 ml of 0.5 mg/ml MTT-media solution
after incubation for 1–4 days. The absorbance was determined at
595 nm using a microplate reader (Bio-Rad Laboratories, iMark).
In all experiments, statistical significance was defined by Pvalues: *P,0.05, **p,0.005, ***p,0.001 (as compared with
control).

Supporting Information

Lentiviral Infection

Figure S1 PAK1 S79A mutation impairs the ability of
Pak1 to change cell morphology. PAK12/2 MEF cells
expressing GFP-PAK1WT (WT) and GFP-PAK1S79A (S79A) were
stained with Phalloidin (red) and DAPI (blue) or visualized by GFP
fluorescence (green).
(TIF)

Lentiviral expression vectors for wild-type GFP-PAK1WT and
mutant GFP-PAK1S79A were constructed by subcloning corresponding cDNAs into pLV-puro lentiviral vector, as described
previously [42]. For viral production, 293T cells were cotransfected with pLV-GFP, pLV- GFP-PAK1WT, or pLV- GFPPAK1S79A, and packaging plasmids (psPAX2 and pCMV-VSV-G)
using CalPhos Mammalian Transfection Kit (Clontech).

Figure S2 MEF cells were stained with the high affinity F-actin
probe Phalloidin (red) after treatment with TAT (a–f) or TATPAK1 peptide (g–l) [43].
(TIF)

Co-immunoprecipitation (IP) and Western Blot Analysis
Cells expressing Pak1, Cdc42, or Rac1 were lysed in lysis buffer
(50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, 10%
glycerol, 1% Triton X100) containing phosphatase inhibitors
(10 mM Na-pyrophosphate, 200 mM Na-orthovanadate, 50 mM
Na-flouride). The cell lysates were incubated with appropriate
antibodies overnight at 4uC. The bound proteins were eluted by
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